Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A (Journal article)
Rizos, C. V./ Liberopoulos, E. N./ Tellis, C. C./ Florentin, M./ Elisaf, M. S./ Tselepis, A. D.
BACKGROUND: Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) and plasma lipoprotein-associated phospholipase A (Lp-PLA) Some sartans partially activate peroxisome proliferator-activated receptor-gamma (PPARgamma), possibly having a favorable effect on metabolic parameters. Telmisartan is the most potent partial PPARgamma activator, followed by irbesartan, whereas olmesartan does not hold such capacity. In an open-label randomized study, we assessed the effects of combining sartans of different PPARgamma- activating capacity with rosuvastatin on LDL subfractions and plasma Lp-PLA in patients with mixed dyslipidemia, hypertension, and prediabetes. METHODS: Following dietary intervention, patients were allocated randomly to rosuvastatin (10 mg/day) plus telmisartan 80 mg/day (RT group, n = 52) or irbesartan 300 mg/day (RI group, n = 48) or olmesartan 20 mg/day (RO group, n = 51). After 6 months of treatment, changes in LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass were evaluated blindly. RESULTS: A total of 151 patients (73 male; mean age 60 years) were included. Large LDL-C decreased in the RT (-36%), RI (-39%), and RO (-41%) groups (P < 0.001 for all vs. baseline). Small dense LDL-C decreased in the RT (-67%), RI (-58%), and RO (-61%) groups (P < 0.001 for all vs. baseline). All regimens increased LDL particle size versus baseline (RT + 1.4%, P = 0.002; RI + 1.0%, P = 0.04; and RO + 1.4%, P = 0.001). No difference for the change of LDL subfractions and LDL size was noticed among groups. Plasma Lp-PLA activity decreased equally in all groups (RT -38%, RI -38%, RO -43%) (P < 0.001 for all vs. baseline). Plasma Lp-PLA mass decreased similarly in all groups versus baseline (RT -28%, P = 0.001; RI -32%, P = 0.01; and RO -27%, P = 0.001). No difference for the change of Lp-PLA mass or activity was noticed among groups. CONCLUSIONS: The combination of rosuvastatin with sartans of different PPARgamma-activating capacity did not differentiate alterations of LDL subfraction cholesterol and plasma Lp-PLA(2) activity and mass.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood/drug effects/metabolism,Aged,Angiotensin II Type 1 Receptor Blockers/*administration & dosage/pharmacology,Benzimidazoles/administration & dosage/pharmacology,Benzoates/administration & dosage/pharmacology,Drug Combinations,Enzyme Activation/drug effects,Female,Fluorobenzenes/*administration & dosage/pharmacology,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration &,dosage/pharmacology,Lipoproteins, LDL/*blood/drug effects/metabolism,Male,Middle Aged,PPAR gamma/*agonists/metabolism,Pyrimidines/*administration & dosage/pharmacology,Sulfonamides/*administration & dosage/pharmacology|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
|Rizos-2011-Combining rosuvastat.pdf||181.95 kB||Adobe PDF||View/Open Request a copy|
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.